Navigation Links
Promising 3-year data: Saving limbs with drug-eluting stents
Date:3/10/2009

SAN DIEGO, Calif. (March 10, 2009)Attempts to treat critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death (gangrene) and amputation. Interventional radiologists have been studying a potential solutionthe use of drug-eluting stentsand have found that these types of stents lessened the rate of repeat procedures to open these small arteries, according to results presented at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

"This is encouraging news for PAD patients with critical limb ischemia. The smaller blood vessels below the knee are more difficult to treat due to their size (3 millimeters) and are more prone to reclog than larger vessels. The use of drug-eluting stents in the tiny infrapopliteal arteries of the leg may significantly impact their care," said Dimitris Karnabatidis, M.D., assistant professor of interventional radiology at Patras University Hospital in Rion, Greece. "Drug-eluting (or drug-coated) stents have emerged as a potential solution to the limitations of endovascular treatment of PAD patients with critical limb ischemia," he added. An interventional radiologist performs a balloon angioplasty to open a clogged blood vessel and then places a drug-eluting stent in that artery. The stent acts as scaffolding to hold the narrowed artery open. Drug-eluting stents slowly release a drug for several weeks to block cell proliferation or regrowth, thus inhibiting restenosis.

Researchers from a single center studied 103 patients in a double-arm prospective registry who had critical limb ischemia and who underwent infrapopliteal revascularization with angioplasty and placement of either a drug-eluting stent (with sirolimus, an immunosuppressant drug
'/>"/>

Contact: Maryann Verrillo
mverrillo@SIRweb.org
703-460-5572
Society of Interventional Radiology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Research uncovers promising target to treat chronic abdominal pain
2. Landscape-scale treatment promising for slowing beetle spread
3. Promising new drug being evaluated as possible treatment option for fragile X syndrome
4. Researchers identify promising gene target for neuroblastoma therapy
5. UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome
6. Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results
7. Promising new treatment option for women with recurrent ovarian cancer
8. Immunotherapy in high-risk pediatric sarcomas shows promising response
9. New treatment approach promising for lymphoma patients in the developing world
10. UIC researchers make promising finding in severe lung disease
11. Biodesigns Rittmann offers promising perspectives on societys energy challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report ... markets for Hand Geometry in US$ Thousands. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... Patients who have high blood sugar before undergoing ... clots, deep vein thrombosis and even pulmonary embolism ... of anesthesiology in the Artificial Pancreas Center at ... Philadelphia, and his colleagues examined records of nearly ...
... protect against some food allergies. Kefir, a traditional fermented drink, ... is often used to wean babies, as it is easily ... the age of three, with around 5-8% of infants at ... food. , "Friendly" bacteria in kefir may play a role ...
... in the event of a large-scale smallpox bioterrorist attack ... by researchers at Fred Hutchinson Cancer Research Center that ... , Instead, the current U.S. government policy of post-release ... workers and close contacts would be sufficient to thwart ...
Cached Biology News:Jefferson scientists find high glucose before surgery raises risk of dangerous complications 2Friendly bacteria in alcoholic milkshake could fight food allergies 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 3Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 4Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 5
(Date:4/21/2015)... , April 21, 2015 ... and development, custom automation, and contract manufacturing, and  ... accessible flow cytometry and cell sorting technology for ... develop a novel flow cytometry platform. ... NanoCellect Biomedical has developed a microchip-based cell sorting ...
(Date:4/21/2015)... 2015  Tute Genomics, a leading provider of cloud-based genomic ... as VP of Marketing. Mr. Forsythe is the latest ... in its commercial operations over the last two quarters. ... Forsythe is a tremendous addition to the Tute Genomics ... Tute Genomics. "Josh,s vast experience commercializing software technology in a ...
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that it will release ... on Tuesday, April 28, 2015. United Therapeutics ... 2015, at 9:00 a.m. Eastern Time.  The teleconference is ... A rebroadcast of the teleconference will be available for ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Whether it’s ... a lab, or bolted to a Kessler CineDrive ... or at the beach, the TS3-H is designed to help ... on a brand-new state-of-the-art 5MP sensor, the TS5-H offers the ... with superior imaging characteristics. , According to Tom Boldt ...
Breaking Biology Technology:NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3
... will potentially enable access to MRI exams for ... implantable cardiac ... Boston,Scientific Corporation (NYSE: BSX ) and Surgi-Vision, ... development arrangement for,magnetic resonance imaging (MRI)-safe technology. Physician implanters ...
... ... 2008, FT. MYERS, Fla., April 15 ... the,Securities and Exchange Commission its annual report on Form 10-KSB for the,year ended ... http://www.SEC.gov ., The audited financial statements for the year ended December ...
... April 15 Arpida Ltd.,(SWX: ARPN) today announced ... Thursday,17 April 2008 at 8.30am CET. In this ... need and developments in the area of anti-infective,drugs ... meeting of the Anti-Infective,Drugs Advisory Committee. During that ...
Cached Biology Technology:Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology 2Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology 3NeoGenomics Files Annual Report on Form 10-KSB with the SEC 2Arpida Announces Conference Call on 17 April 2Arpida Announces Conference Call on 17 April 3
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Polymerase (RNA) II (DNA directed) polypeptide L...
...
...
Biology Products: